advertisement
11.3.4 Betablocker (16)
Showing records 1 to 16
Display all abstracts in classification 11.3.4 Betablocker
Search within classification 11.3.4 Betablocker8271 Progression of retinal nerve fibre layer damage in betaxolol- and timolol-treated glaucoma patients
Vainio-Jylhä E; Vuori ML; Nummelin K
Acta Ophthalmologica Scandinavica 2002; 80: 495-500
8299 Efficacy of brimonidine 0.2 per cent as adjunctive therapy to beta-blockers: a comparative study between POAG and CACG in Asian eyes
Ruangvaravate N; Kitnarong N; Metheetrairut A; Danwiriyakul W
Journal of the Medical Association of Thailand 2002; 85: 894-900
8083 Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy
Calissendorff B; Sjoquist B; Hogberg G; Grunge-Lowerud A
Journal of Ocular Pharmacology and Therapeutics 2002; 18: 127-131
8087 Betaxolol, a beta-1-adrenoceptor antagonist, protects a transient ischemic injury of the retina
Cheon EW; Kim YH; Cho YY; Kim HJ; Kang SS; Cho GJ; Yoo JM; Song JK; Choi WS
Experimental Eye Research 2002; 75: 591-601
8225 Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative
Hamard P; Debbash C; Blondin C; Brignole F; Loison-Dayma K; Warnet JM; Baudouin C
Journal Français d'Ophtalmologie 2002; 25: 777-784
8082 One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension
Higginbotham EJ; Schuman JS; Goldberg I; Gross RL; VanDenburgh AM; Chen K; Whitcup SM
Archives of Ophthalmology 2002; 120: 1286-1293
8084 Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity
Ishii Y; Nakamura K; Matsuki S; Uemura N; Muraguchi R; Nakagawa M; Nakano S; Nakatsuka K
Journal of Clinical Pharmacology 2002; 42: 1020-1026
8333 Serum lipid profile and timolol gel
Khamar MB; Bhatt N; Patel K
Journal of the Indian Medical Association 2002; 100: 620-621
8253 Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment
Lama PJ
American Journal of Ophthalmology 2002; 134: 749-760
8081 Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys
Mizuno K; Koide T; Saito N; Fujii M; Nagahara M; Tomidokoro A; Tamaki Y; Araie M
Investigative Ophthalmology and Visual Science 2002; 43: 3243-3250
8258 A comparison of the fixed combination of latanoprost and timolol with its individual components
Pfeiffer N
Graefe's Archive for Clinical and Experimental Ophthalmology 2002; 240: 893-899
8088 Timolol 0.1% gel (Nyogel® 0.1%) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety
Rouland JF; Morel-Mandrino P; Elena PP; Polzer H; Sunder Raj P
Ophthalmologica 2002; 216: 449-454
8347 The safety and efficacy of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%
Stewart WC; Sharpe ED; Stewart JA; Hott CE
Current Eye Research 2002; 24: 387-391
8085 Protective action of nipradilol against ischemia-induced retinal damage in rats
Taniai M; Sato E; Mizota A; Adachi-Usami E
Ophthalmic Research 2002; 34: 331-337
8086 Vasodilatory effects of nipradilol, an α- and β-adrenergic blocker with nitric oxide releasing action, in rabbit ciliary artery
Yoshitomi T; Yamaji K; Ishikawa H; Ohnishi Y
Experimental Eye Research 2002; 75: 669-676
8273 A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma
Honrubia EM; Larsson LI; Spiegel D; European Latanoprost Study Group
Acta Ophthalmologica Scandinavica 2002; 80: 635-641